Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034370 | 1.00 | HTR6 (0.70) | HTR6 | |
| SCHEMBL315531 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL316539 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315805 | 0.82 | HTR6 (0.80) | HTR6 | |
| SCHEMBL315674 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL315673 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL17361504 | 0.81 | HTR6 (0.79) | HTR6 | |
| SCHEMBL7787639 | 0.81 | CA12 (0.51) | HTR6 | |
| SCHEMBL21870098 | 0.80 | HTR6 (0.59) | HTR6 | |
| SCHEMBL314928 | 0.79 | HTR6 (1.00) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076489-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | claimed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | claimed |
| EP-2076489-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.